Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosneft's IFRS profit in 2022 decreased by 8%

3/20/23 ROSN

Board of Directors of Inter RAO recommended that dividends be paid for 2022

3/20/23 IRAO

Profit of Kazatomprom in 2022 doubled

3/20/23 KAP

Profit of Lenzoloto according to RAS in 2022 increased by 25 times

3/20/23 LNZL

Kamaz will supply Mosgortrans with 1,000 electric buses in 2023-2024

3/20/23 KMAZ

RusAgro is listed in Kazakhstan

3/20/23 RAGR

Sovcomflot will allocate at least 50% of adjusted IFRS profit to dividends

3/20/23 FLOT

Fesco launched a new intermodal route from Moscow to Kaliningrad via St. Petersburg

3/20/23 FESH

Magnit will launch a center for growing greens in 2024

3/20/23 MGNT

Sovcomflot reported for 2022 according to IFRS

3/20/23 FLOT